Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?

CRISPR Therapeutics (CRSP) is anticipated to report a Q3 2025 loss of $1.32 per share on $6.71 million in sales, with a positive Earnings ESP of +3.53% and a Zacks Rank #3 indicating a potential earnings beat, consistent with its historical performance. Key investor focus will be on the rising sales of its first commercial product, Casgevy, developed with Vertex Pharmaceuticals, which is expected to improve collaboration expenses, alongside updates on its extensive pipeline of CAR-T and in-vivo gene editing candidates. While pipeline development is increasing operating expenses, it positions CRSP with a first-mover advantage and offers significant future growth catalysts.

Analysis

CRISPR Therapeutics (CRSP) is anticipated to report a Q3 2025 loss of $1.32 per share on $6.71 million in sales. Despite a slight widening of 2025 loss per share estimates to $6.66, the company holds a positive Earnings ESP of +3.53% and a Zacks Rank #3, indicating a high probability of an earnings beat. This aligns with CRSP's strong historical performance, having surpassed estimates in three of the last four quarters with an average surprise of 18.41%.

The commercial progress of Casgevy, CRSP's first and only marketed product developed with Vertex Pharmaceuticals (VRTX), will be a key focus, with rising sales expected to improve collaboration expenses. Investors will also monitor updates on its extensive pipeline, including two next-generation CAR-T candidates (CTX112, CTX131) in Phase I/II studies and two in-vivo candidates (CTX310, CTX320) in Phase I. The company plans to advance two additional in-vivo programs (CTX340, CTX450) to clinical development by year-end.

Increased operating expenses from pipeline development are likely to pressure near-term loss estimates, yet these investments underscore CRSP's long-term growth strategy and first-mover advantage in gene editing over peers like Beam Therapeutics (BEAM) and Intellia Therapeutics (NTLA). CRSP's shares have significantly outperformed, surging approximately 63% year-to-date against the industry's 12% growth, and trade at a modest price-to-book discount relative to the industry. The Vertex partnership further strengthens commercial execution.

Key Decisions for Investors

• Monitor Q3 earnings for Casgevy sales trajectory and any specific guidance on pipeline advancements, particularly for CAR-T and in-vivo candidates.
• Consider the long-term growth potential driven by CRSP's first-mover advantage with Casgevy and its robust, albeit early-stage, pipeline, despite anticipated near-term operating losses.
• Evaluate the impact of rising operating expenses as an investment in future innovation, balancing short-term profitability concerns with long-term strategic positioning in the gene editing space.